I think it's fairly common to short biotech stocks that are in early stages before quarterly earnings reports. These companies usually report big losses because they have lots of expenses and little to no revenue. The stock usually goes down after earnings reports. They will probably cover after they think it has hit bottom.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.